FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 113 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 469.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $59,000 | -23.4% | 12,601 | 0.0% | 0.00% | -100.0% |
Q2 2020 | $77,000 | +165.5% | 12,601 | 0.0% | 0.00% | – |
Q1 2020 | $29,000 | -50.0% | 12,601 | 0.0% | 0.00% | – |
Q4 2019 | $58,000 | +18.4% | 12,601 | 0.0% | 0.00% | – |
Q3 2019 | $49,000 | -35.5% | 12,601 | 0.0% | 0.00% | – |
Q2 2019 | $76,000 | -56.1% | 12,601 | 0.0% | 0.00% | -100.0% |
Q1 2019 | $173,000 | +53.1% | 12,601 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $113,000 | -35.8% | 12,601 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $176,000 | -11.6% | 12,601 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $199,000 | -8.3% | 12,601 | -0.1% | 0.00% | -50.0% |
Q1 2018 | $217,000 | -21.4% | 12,610 | +0.1% | 0.00% | 0.0% |
Q4 2017 | $276,000 | -46.5% | 12,601 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $516,000 | +36.1% | 12,601 | 0.0% | 0.00% | +33.3% |
Q2 2017 | $379,000 | -16.9% | 12,601 | 0.0% | 0.00% | -25.0% |
Q1 2017 | $456,000 | -27.7% | 12,601 | 0.0% | 0.00% | -33.3% |
Q4 2016 | $631,000 | – | 12,601 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |